Table 1 Basic demographics and baseline clinical data
Group(n) | Placebo (26) | WLT (52) | Tolterodine (52) | Combination (52) | P-value |
|---|---|---|---|---|---|
Age (y) | 47(27–72) | 49 (25–71) | 48 (26–73) | 48 (28–75) | 0.832 |
OABSS | 9.2 ± 2.6 | 8.9 ± 2.2 | 9.1 ± 2.8 | 9.6 ± 2.5 | 0.252 |
Voids/24 h | 13.5 ± 2.9 | 13.0 ± 2.1 | 13.2 ± 2.8 | 13.8 ± 2.3 | 0.096 |
VV (ml) | 140 ± 35 | 143 ± 22 | 141 ± 36 | 142 ± 31 | 0.887 |
Patients with UI | 20 | 42 | 40 | 43 | 0.874 |
UI/24 h | 1.10 ± 0.98 | 1.06 ± 0.96 | 0.97 ± 0.96 | 1.13 ± 1.05 | 0.783 |
RU (ml) | 6.8 ± 9.7 | 5.6 ± 8.8 | 7.1 ± 9.8 | 6.2 ± 9.1 | 0.759 |